MedTrace Logo

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

NCT04260802 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2026-01-12

No results posted yet for this study

Summary

This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types

Conditions

Interventions

DRUG

OC-001

Administered IV.

DRUG

Drug: OC-001 in Combination with Avelumab

Administered IV.

Sponsors & Collaborators

  • Ocellaris Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Ocellaris Pharma, Inc · Ocellaris Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2025-11-07
Completion
2025-11-07

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260802 on ClinicalTrials.gov